Pivotal Point Follow-Up Moderna (MRNA): Shift Away from COVID Focus After Breakthrough in Personalized Cancer Immunotherapy!

Moderna is a pioneer in mRNA technology and gained worldwide recognition through the success of its COVID-19 vaccine. On February 18, positive Phase 3 data for a personalized cancer vaccine in combination with Pembrolizumab triggered a surge in stock prices. The company is increasingly focusing on oncology and rare diseases to reduce its dependence on the seasonal vaccine business. With a robust pipeline of over 40 programs, the corporation is currently transforming into a broadly focused specialist in gene medicine and immunotherapy. The biotech...